Johany Velazquez, Inarvis Bonilla, Luis Chiroque, and Trinidad Garcia. STD/HIV/AIDS PREVENTION PROGRAM, Puerto Rico Department of Health, PO Box San Juan, PR 00936-8184, San Juan, PR, USA
Background:
The Chlamydia trachomatis (Ct) infection is the most frequently reported STD in Puerto Rico (PR). Gonorrhea (GC) is the second most commonly reported notifiable disease in PR. PR Infertility Prevention Project (IPP) promotes the screening among women in childbearing age in different provider types around the island.
Objective:
To describe the positivity of chlamydia and co-infection with gonorrhea in women aged 15-30 years screened in different provider types during the period 2003-2005.
Method:
Data were analyzed on 26,720 tests on women aged 15-30 years screened for Ct in different provider types. Ct positivity and GC positivity among women infected with Ct were calculated by provider type and age group (15-22 and 23-30 years).
Result:
The Ct positivity was 6.6% among women 15-30 years. For women 15-22 years the Ct positivity was 8.4% and 4.5% among women 23-30 years. The GC positivity was 0.6% among women 15-30 years. Among women 15-22 years, the Ct positivity was highest in the Detention Centers (14.9%) followed by the STD Clinics (12.4%) and Prenatal Clinics (11.7%); among women 23-30 years, the Ct positivity was highest in the STD Clinics (9.4%) followed by the Detention Centers (7.7%) and Prenatal Clinics (5.4%). The GC positivity was highest in STD Clinics (1.9% women 15-22 years and 2.0% women 23-30 years). GC positivity among those women infected with Ct was 1.4%; it was highest among those 23-30 years (1.6%), compared with 15-22 years.
Conclusion:
The Ct positivity is highest among women 15-21 years of age. The STD Clinics, the Detention Centers and Prenatal Clinics were the providers with highest Ct positivity. GC positivity among those women infected with Ct was less than 2.0%.
Implications:
This analysis indicates the continued importance of Ct screening among women in childbearing age, but considering the clinical settings to promote the screening.